ADMA Biologics Announces Poster Presentation Highlighting Pharmacoeconomic Burden of HIV and HBV Infection in Sexual Assault Patients at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting

Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection

Healthcare Costs Associated with HBV and HIV are Approximately at Parity; HBV Carries 50-100 Times Greater Transmission Risk Compared to HIV

Pharmacoeconomic Analysis and Unmet Patient Need Strongly Support Harmonization of HBV and HIV CDC Treatment Guidelines for Sexual Assault Victims

RAMSEY, N.J. and BOCA RATON, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting (“AMCP”) taking place April 12-16, 2021.

“Current CDC guidelines for post-exposure prophylaxis of suspected Hepatitis B infection (“HBV”) offer no intervention for sexual assault victims with perpetrators of unknown Hepatitis B surface antigen status,” said Adam Grossman, President and Chief Executive Officer of ADMA.  “HBV is significantly more infectious than is HIV, and can be transmitted by any bodily fluid, and amounts to a roughly equivalent cost burden for the US healthcare system. Our analysis suggests that amending CDC guidelines in this at-risk population for HBV to mirror those of HIV and specifically mandating a Hepatitis B Globulin intervention like ADMA’s Nabi-HB hyperimmune, will provide a cost-effective strategy for prophylactic seroprotection of these vulnerable patients. It is our hope that lobby groups advocating on behalf of at-risk patients will leverage this analysis to convey to policymakers that failing to address this patient population, and harmonizing treatment guidelines between HIV and HBV, may have considerable clinical and cost implications for the US healthcare system.”

Details for the AMCP 2021 poster presentation are as follows:

Poster Title: Pharmacoeconomic Analysis Comparing Medical Costs for Prophylaxis of HIV and HBV Infection in Sexual Assault Patients

Author: Gruenglas, Pantello, Mond
Session Title: Poster Abstract Sessions
Session Dates: Tuesday, April 13 – Wednesday, April 14, 2021 (2:30 pm ET)
Session Location: Virtual Poster Hall
Poster No: B3   

View the presentation at the virtual 2021 AMCP Annual Meeting

About Nabi-HB

Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg), prenatal exposure to infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem and can cause chronic infection and put people at high risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. Certain data and other information about Nabi-HB or ADMA Biologics and its products can be found on the Company’s website at www.admabiologics.com.